Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HER2 testing: laboratory, technical and clinical considerations.

L G Dressler1, A D Thor

  • 1University of North Carolina, Lineberger Comprehensive Cancer Center, Department of Medicine, Chapel Hill, North Carolina 27599-7295, USA. dressler@med.unc.edu

Breast Disease
|February 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer.

Journal of oncology translational research·2018
Same author

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.

Clinical and translational science·2017
Same author

Preferences for return of incidental findings from genome sequencing among women diagnosed with breast cancer at a young age.

Clinical genetics·2015
Same author

Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells.

Oncogene·2010
Same author

How will GINA influence participation in pharmacogenomics research and clinical testing?

Clinical pharmacology and therapeutics·2009
Same author

Handling, storage, and preparation of human tissues.

Current protocols in cytometry·2008
Same journal

Paget disease of the breast: An often-overlooked malignancy.

Breast disease·2026
Same journal

Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy.

Breast disease·2025
Same journal

Association between AKT1 polymorphisms and susceptibility to breast cancer in the Iranian population.

Breast disease·2025
Same journal

Circulating tumor cells as a clinical, diagnostic, and prognostic biomarker in breast cancer.

Breast disease·2025
Same journal

Isolated breast myeloid sarcoma: A diagnostic and therapeutic challenge. A case report and literature review.

Breast disease·2025
Same journal

Imaging evaluation of nipple discharge: Review of literature and management considerations.

Breast disease·2025
See all related articles

HER2 testing is crucial for breast cancer treatment selection. However, current methods for measuring HER2 status have uncertainties in accuracy and clinical utility, requiring standardization for reliable patient management.

Area of Science:

  • Oncology
  • Biomarker Analysis
  • Molecular Diagnostics

Background:

  • HER2 (Human Epidermal growth factor Receptor 2) measurement is vital for predicting systemic therapy response in breast cancer.
  • Clinical enthusiasm for HER2 is challenged by uncertainty in the accuracy and usefulness of current assessment methodologies.
  • Laboratory and technical issues impact the reliability of HER2 overexpression and amplification measurements.

Purpose of the Study:

  • To address laboratory and technical challenges in HER2 measurement methods.
  • To discuss how these issues affect the clinical utility and routine application of HER2 as a tumor marker.
  • To highlight the need for validation of HER2 testing methods for predicting treatment response.

Main Methods:

  • Review of laboratory and technical issues in HER2 assessment.

Related Experiment Videos

  • Discussion of the influence of these issues on clinical utility.
  • Analysis of criteria for clinical relevance and usefulness of tumor markers.

    • Main Results:

    • Current HER2 testing methodologies face uncertainties regarding accuracy and clinical usefulness.
    • Technical and laboratory issues can compromise the reliability of HER2 status assessment.
    • Standardization and validation are necessary for routine clinical application of HER2 testing.

    Conclusions:

    • HER2 testing requires standardized, reliable, and reproducible methods for clinical utility.
    • Clinical validation through randomized trials is essential to confirm HER2's predictive value.
    • Establishing clear standards for assay performance and result interpretation is critical for routine HER2 testing.